Article Versions Notes

Dang C, Ewer MS, Delaloge S, Ferrero J-M, Colomer R, de la Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, et al. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers. 2022; 14(11):2596. https://doi.org/10.3390/cancers14112596

Dang, Chau, Michael S. Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L. Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger, and et al. 2022. "BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer" Cancers 14, no. 11: 2596. https://doi.org/10.3390/cancers14112596

Dang, C., Ewer, M. S., Delaloge, S., Ferrero, J. -M., Colomer, R., de la Cruz-Merino, L., Werner, T. L., Dadswell, K., Verrill, M., Eiger, D., Sarkar, S., de Haas, S. L., Restuccia, E., & Swain, S. M. (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers, 14(11), 2596. https://doi.org/10.3390/cancers14112596